Sunshine Biopharma Inc. (NASDAQ: SBFM) announced the closing of its previously announced public offering, generating approximately $6 million in gross proceeds before fees and expenses. The company sold 12 million common units, each consisting of either common stock or pre-funded warrants and two Series C warrants. Aegis Capital acted as the exclusive placement agent for the offering.
The net proceeds from the offering are expected to be used for general corporate purposes and working capital. Additionally, if the Series C warrants are fully exercised for cash, the company could receive up to approximately $12 million in additional gross proceeds. This capital infusion comes at a critical time as Sunshine Biopharma continues to expand its commercial operations and advance its pipeline.
Sunshine Biopharma currently markets 60 generic prescription drugs in Canada, with plans to launch 12 additional products for the remainder of 2026. The company is also focused on two proprietary drug development programs: K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic candidate targeting liver cancer, and a PLpro protease inhibitor, a small-molecule antiviral candidate for SARS-related coronavirus infections. These programs represent potential growth drivers beyond the company's existing generic drug business.
The successful closing of the offering underscores investor interest in Sunshine Biopharma's strategy of combining a stable revenue stream from generic drugs with high-potential proprietary therapeutics. For readers, this news matters because it provides the company with financial runway to execute its business plan, which could lead to new treatment options for liver cancer and coronavirus infections, as well as an expanded portfolio of affordable generic medications in Canada.
More details about the offering can be found in the full press release at https://ibn.fm/XuHPC. Additional information about Sunshine Biopharma is available on its website at https://sunshinebiopharma.com/.
